ABVC BioPharma (ABVC) Q2 2025 earnings summary

Executive summary

• Net loss for Q2 2025 increased to $2.33M from $1.05M in Q2 2024, mainly due to higher consulting and advisory expenses.

• Revenue for Q2 2025 was $0, down from $117K in Q2 2024, reflecting no milestone receipts in the period.

• Total consolidated assets reached $16.2 million in Q2 2025, up 103% year-over-year, reflecting stronger affiliate equity and asset allocation.

• Shareholders' equity increased to $9.5 million from $8.0 million in Q2 2024, driven by strategic consolidation and improved capital structure.

• The company continues to focus on plant-derived drug and device development, with several clinical trials ongoing or planned.

Financial highlights

• Q2 2025 net loss: $2.33M, up 123% from Q2 2024; six-month net loss: $3.28M, down 18% from prior year.

• Q2 2025 revenue: $0; six-month 2025 revenue: $0, compared to $118K in 2024.

• Operating expenses for Q2 2025: $2.29M, up from $977K in Q2 2024; six-month 2025 operating expenses: $2.99M, down from $3.82M in 2024.

• Cash and cash equivalents as of June 30, 2025: $388K; working capital deficit: $3.76M.

• Asset base more than doubled year-over-year, primarily due to affiliate equity and asset allocation improvements.

Outlook and guidance

• Management plans to improve cash flows by collecting licensing payments, raising capital, controlling expenses, and reducing debt.

• $350,000 in licensing revenue collected in July 2025 will be recognized in Q3, supporting a positive revenue outlook.

• Ongoing liquidity concerns due to recurring losses and negative cash flows; ability to continue as a going concern depends on successful fundraising and operational improvements.

• Several clinical trials are ongoing or planned, with potential for future milestone and royalty revenues.